Clinical Trials
5 trialsNCT04660929 2024-12-18
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
Phase 1 Unknown
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed
NCT00106002 2009-06-01
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00461344 2008-04-03
Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
Sanofi
Phase 2 Terminated